Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease

Abstract Objective To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders. Methods This prospective study enrolled 216 iPD patients, 1...

Full description

Bibliographic Details
Main Authors: Shin‐Ichi Ueno, Taku Hatano, Ayami Okuzumi, Shinji Saiki, Yutaka Oji, Akio Mori, Takahiro Koinuma, Motoki Fujimaki, Haruka Takeshige‐Amano, Akihide Kondo, Naoyuki Yoshikawa, Takahiro Nojiri, Makoto Kurano, Keiko Yasukawa, Yutaka Yatomi, Hitoshi Ikeda, Nobutaka Hattori
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.50990
id doaj-e9eda1b5376749098574688418ee6a8b
record_format Article
spelling doaj-e9eda1b5376749098574688418ee6a8b2021-05-02T21:13:20ZengWileyAnnals of Clinical and Translational Neurology2328-95032020-03-017330731710.1002/acn3.50990Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 diseaseShin‐Ichi Ueno0Taku Hatano1Ayami Okuzumi2Shinji Saiki3Yutaka Oji4Akio Mori5Takahiro Koinuma6Motoki Fujimaki7Haruka Takeshige‐Amano8Akihide Kondo9Naoyuki Yoshikawa10Takahiro Nojiri11Makoto Kurano12Keiko Yasukawa13Yutaka Yatomi14Hitoshi Ikeda15Nobutaka Hattori16Department of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurosurgery Faculty of Medicine Juntendo University Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory Medicine Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Clinical Laboratory Medicine Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanAbstract Objective To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders. Methods This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters. Results iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA. Interpretation %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms.https://doi.org/10.1002/acn3.50990
collection DOAJ
language English
format Article
sources DOAJ
author Shin‐Ichi Ueno
Taku Hatano
Ayami Okuzumi
Shinji Saiki
Yutaka Oji
Akio Mori
Takahiro Koinuma
Motoki Fujimaki
Haruka Takeshige‐Amano
Akihide Kondo
Naoyuki Yoshikawa
Takahiro Nojiri
Makoto Kurano
Keiko Yasukawa
Yutaka Yatomi
Hitoshi Ikeda
Nobutaka Hattori
spellingShingle Shin‐Ichi Ueno
Taku Hatano
Ayami Okuzumi
Shinji Saiki
Yutaka Oji
Akio Mori
Takahiro Koinuma
Motoki Fujimaki
Haruka Takeshige‐Amano
Akihide Kondo
Naoyuki Yoshikawa
Takahiro Nojiri
Makoto Kurano
Keiko Yasukawa
Yutaka Yatomi
Hitoshi Ikeda
Nobutaka Hattori
Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
Annals of Clinical and Translational Neurology
author_facet Shin‐Ichi Ueno
Taku Hatano
Ayami Okuzumi
Shinji Saiki
Yutaka Oji
Akio Mori
Takahiro Koinuma
Motoki Fujimaki
Haruka Takeshige‐Amano
Akihide Kondo
Naoyuki Yoshikawa
Takahiro Nojiri
Makoto Kurano
Keiko Yasukawa
Yutaka Yatomi
Hitoshi Ikeda
Nobutaka Hattori
author_sort Shin‐Ichi Ueno
title Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
title_short Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
title_full Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
title_fullStr Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
title_full_unstemmed Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
title_sort nonmercaptalbumin as an oxidative stress marker in parkinson’s and park2 disease
publisher Wiley
series Annals of Clinical and Translational Neurology
issn 2328-9503
publishDate 2020-03-01
description Abstract Objective To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders. Methods This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters. Results iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA. Interpretation %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms.
url https://doi.org/10.1002/acn3.50990
work_keys_str_mv AT shinichiueno nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT takuhatano nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT ayamiokuzumi nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT shinjisaiki nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT yutakaoji nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT akiomori nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT takahirokoinuma nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT motokifujimaki nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT harukatakeshigeamano nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT akihidekondo nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT naoyukiyoshikawa nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT takahironojiri nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT makotokurano nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT keikoyasukawa nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT yutakayatomi nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT hitoshiikeda nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
AT nobutakahattori nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease
_version_ 1721487374699986944